Abstract 1853P
Background
Frankl's Logotherapy is a psychotherapeutic approach aimed at finding meaning in life. Although the incidence of death anxiety, existential loneliness, and depression in cancer patients is high, the efficacy of Logotherapy in this population is not well established.
Methods
Two independent investigators searched PubMed, Embase, and Cochrane Library databases up to March 2023. We systematically reviewed, according to PRISMA guidelines, controlled clinical trials evaluating the use of Logotherapy in cancer anxiety symptoms. We performed a pooled analysis on anxiety scores of patients that underwent group Logotherapy sessions vs. non-exposed control groups.
Results
We included seven studies, four randomized controlled trials (RCTs), and three quasi-experimental, comprising 280 patients, published between 1977 and 2023. A total of 139 patients (49.6%) had sessions of Logotherapy, and ages ranged from 18 to more than 68 years. Total treatment duration ranged between 360 and 1200 minutes. The Standard Mean Difference (SMD) for anxiety symptoms was -1.63 (95% CI = [-2.65, -0.61]; z = 3.12; P = 0.002; I2 = 92%) in patients who underwent Logotherapy compared to non-exposed control groups. In a subgroup analysis including only RCTs, a similar effect was observed with an SMD of -0.64 (95% CI = [-1.72, 0.44]; z = 1.16; P = 0.25; I2 = 91%).
Conclusions
Despite limited evidence, Logotherapy group sessions were associated with a reduction in anxiety scores of adult patients with cancer when compared to inactive control groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.V. Teixeira Filho.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05